Despite a recent surge in GM's stock price, Bernstein analysts warn of potential earnings headwinds and increased capital requirements, leading to a lowered price target.
According to the firm, GM's stock has surged by 85% since November 2023, thanks to strong North American performance and aggressive shareholder returns, including a $10 billion accelerated share repurchase in late 2023 and an additional $6 billion buyback in mid-2024.
First, the U.S. inventory buildup is expected to create pricing pressures next year. Second, delays in ramping up electric vehicle production and continued losses from GM’s autonomous vehicle division, Cruise, are expected push earnings headwinds into 2025. International business challenges are also adding to the pressure.
Bernstein has slightly increased its capital expenditure forecast to the higher end of GM’s guidance, further reducing its 2025 FCF estimate to $6 billion.
GM Bernstein Earnings Capital Expenditures Price Target
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bitcoin (BTC) Price: Top Trader Weighs In on $250,000 Price TargetCan Bitcoin still reach $250,000 next year?
Read more »
2025 Hyundai Sonata Gains Entry-Level SE Trim, Lowers Starting Price By $850The Sonata SE returns for 2025 and it lowers the price of entry to $26,650
Read more »
Eli Lilly lowers Zepbound price and Harris campaign hits Trump on fiscal agenda: Morning RundownBlockbuster drugs Ozempic and Wegovy have sparked conversation and changed weight loss worldwide. In an exclusive interview, NBC News’ Megan Fitzgerald sits down with Novo Nordisk CEO Lars Fruergaard Jørgensen who helmed it all, and presses him on the high price, drug shortages, and long-term effects.
Read more »
Zepbound price cut: Eli Lilly lowers cost of weight loss drugBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Read more »
AUD/USD Price Forecast: Price is at a crossroads – is it correcting or reversing lower?AUD/USD has been in an uptrend all through August. It reached a new peak of 0.6824 on August 29 and then pulled back.
Read more »
NZD/USD Price Prediction: Uptrend still intact as price pushes against range highsNZD/USD reversed course after breaking out of the top of its consolidation range.
Read more »